Lymphoma News TodayBenefits of 2 CAR T-cell Therapies May Justify Their High Price, ICER Report ArguesLymphoma News TodayTwo CAR T-cell therapies are now FDA-approved, Yescarta (axicabtagene ciloleucel) for people with advanced large B-cell lymphoma, a… Continue reading
CRISPR Could Yield $25B in Revenues by 2030hcanews.comCompanies using applications of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing technology might rake in as much as $25 billion in revenues by the 2030s, according … Continue reading
fox6now.comFDA approves gene therapy for a type of blindness | FOX6Now.comfox6now.comThe US Food and Drug Administration has approved a gene therapy treatment for patients with a rare inherited eye disease. Voretigene neparvovec, which will be sold as … Continue reading
PharmaTimes |
J&J enters CAR–T field with $350M Legend deal
BioPharma Dive Johnson & Johnson has bought itself a foothold in the accelerating CAR–T field, paying $350 million upfront through its subsidiary Janssen Biotech Inc. to gain access to a cancer cell therapy candidate developed by a previously little-known Chinese … Janssen buys into Legend’s CART therapyPharmaTimes Chinese biotech firm Genscript’s shares jump by a third on US$350m Johnson & Johnson unit tie-upSouth China Morning Post |
Futurism |
The FDA Approves a New Gene Therapy Treatment for a Rare Form of Blindness
Futurism The U.S. Food and Drug Administration (FDA) has approved the use of a new form of gene therapy that targets a rare inherited eye disease. The FDA panel had voted to approve the therapy back in October. The treatment, voretigene neparvovec, will now be … Gene therapy could prevent blindnessInnovators Magazine FDA approves Spark’s gene remedy for uncommon blindness pioneered at CHOPKaplan Herald |